InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
9
T+90 hit rate
0%
T+90 mean return
-62.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by NORTHCOTT JOHN, Directeur Commercial. Officer active across 2 companies, notably Nektar Therapeutics. Cumulatively, 11 disclosures have been logged. Split: 0 buy · 9 sells. Total volume traded: €580k. History available since 17 May 2021. The latest transaction was filed on 16 May 2022 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
4,592 shares@ US$3.950.0007% mcap3.0% of flowCommon StockSEC:0001209191-22-029900:0
4,852 shares@ US$10.950.0020% mcap8.1% of flowCommon StockSEC:0001209191-22-011437:0
4,852 shares@ US$10.950.0020% mcap16.6% of flowCommon StockSEC:0001209191-22-011437
37,800 shares0Common StockSEC:0001209191-21-070691
37,800 shares0Common StockSEC:0001209191-21-070691:0
6,061 shares@ US$13.160.0029% mcap12.1% of flowCommon StockSEC:0001209191-21-065221:0
6,061 shares@ US$13.1612.1% of flowCommon StockSEC:0001209191-21-065221
6,192 shares@ US$13.830.0030% mcap12.5% of flowCommon StockSEC:0001209191-21-052385:0
6,192 shares@ US$13.8312.5% of flowCommon StockSEC:0001209191-21-052385
6,085 shares@ US$18.3015.8% of flowCommon StockSEC:0001209191-21-034186
6,085 shares@ US$18.300.0038% mcap15.8% of flowCommon StockSEC:0001209191-21-034186:0
11 of 11 declarations
About NORTHCOTT JOHN
John Northcott is Senior Vice President and Chief Commercial Officer at Nektar Therapeutics. He oversees the company's commercial and marketing efforts, ensuring that products effectively reach the market. His experience in the biopharmaceutical industry is crucial for the organization's success.
